Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia; and FHD-609, a small molecule protein degrader of BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. Foghorn Therapeutics Inc. has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel therapeutics based on disruptors of a specified transcription factor target. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2020
Exchange: NASDAQ
Website: foghorntx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/23/2025 | $9.00 | Mkt Outperform | Citizens JMP |
| 1/30/2025 | $10.00 | Buy | B. Riley Securities |
| 9/3/2024 | $18.00 | Buy | Jefferies |
| 8/19/2024 | $20.00 | Outperform | Evercore ISI |
| 3/28/2023 | $10.00 | Buy | BofA Securities |
| 1/5/2023 | $20.00 | Outperform | BMO Capital Markets |
| 12/15/2021 | $23.00 → $26.00 | Overweight | Morgan Stanley |
| 11/22/2021 | $25.00 | Buy | HC Wainwright & Co. |
CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the Citizens Life Sciences Conference, being held May 7-8, 2025, in New York, NY. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases. Fireside Chat Data and Time: Wednesday, May 7, 2025, at 9:30 a.m. ESTPresenter: Adrian Gottschalk, President and Chief Executi
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the election of Neil Gallagher, M.D., Ph.D., and Stuart Duty, to its Board of Directors. "Neil and Stuart are experienced leaders with decades of deep and multifaceted understanding of the biotechnology industry," said Adrian Gottschalk, President and Chief Executive Officer of Foghorn. "We are pleased to welcome them to our Board of Directors and will leverage their strategic insights as we further advance our pipeline." Dr. Gallagher
CAMBRIDGE, Mass., April 29, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Quotient Therapeutics, a company pioneering somatic genomics, today announced that Rahul Kakkar, M.D., will join Flagship Pioneering as CEO-Partner and Quotient Therapeutics as Chief Executive Officer. Dr. Kakkar is a biotech entrepreneur and physician-scientist with nearly 20 years of professional experience founding and building biotechnology companies and practicing medicine. Previously, he served as President and CEO of Tome Biosciences, a genome engineering biotec
- FHD-909 (LY4050784) advancing in Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population - Preclinical synergistic anti-tumor activity of FHD-909 in combination with pembrolizumab and KRAS inhibitors supports clinical exploration - Selective CBP degrader combination approaches show promise in preclinical ER+ breast cancer models - Further preclinical characterization of the therapeutic potential of the Selective EP300 degrader program to treat advanced hematological malignanciesVirtual investor event Tuesday, April 29, 2025, at 8 a.m. ET CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Foghorn® Th
Etiome's Temporal Biodynamics™ AI-powered platform is the first end-to-end solution to detect disease and preempt progression before it becomes too late Company emerges following four years of platform development and an initial commitment of $50 million from Flagship Pioneering CAMBRIDGE, Mass., April 24, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today unveiled Etiome, a company redefining how we detect and preempt disease progression. Etiome's Temporal Biodynamics™ platform is the first end-to-end technology to characterize disease with increased resolution over time and accelerate the development of preemptive medicines that promise better health outcom
Company to share new preclinical combination data for FHD-909 (LY4050784), a potential first-in-class selective SMARCA2 inhibitor, with non-small cell lung cancer (NSCLC) as the primary target population Additional updates include new preclinical data for Selective CBP degrader program in combination with chemotherapy and targeted agents and for Selective EP300 degrader program in hematological malignancies Virtual investor event to be held on Tuesday April 29, 2025, at 8 a.m. ET CAMBRIDGE, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by co
Collaboration leverages Logica, a platform offering from Valo Health and Charles River that directly translates biological insights into optimized small molecules Sixth agreement signed under strategic partnership between Flagship Pioneering and Pfizer to accelerate discovery of innovative compounds that may become medicines targeting unmet needs CAMBRIDGE, Mass., April 1, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced an agreement between Pioneering Medicines, Flagship's in-house drug discovery and development unit, and Pfizer, to discover compounds which may lead to the development of next-generation therapeutics for autoimmune diseases.
First Logica-identified candidate marks a progression-based milestone in ongoing partnership with Pioneering Medicines, Flagship Pioneering's in-house drug development unit Charles River Laboratories International, Inc. (NYSE:CRL) and Valo Health, Inc. today announced the identification of an advanceable product candidate for the treatment of different forms of lupus and other autoimmune indications with significant unmet need. The discovery is the first using Logica®, an artificial intelligence (AI)-powered drug development solution that translates biological insights into optimized preclinical assets. "Identification of this first lead candidate provides proof-of-concept for Logica as a
AI platform combined with autonomous labs will accelerate discovery across every domain of science Company has raised $200M in seed financing to further develop platform and build first AI Science Factories CAMBRIDGE, Mass., March 10, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today unveiled Lila Sciences, a company building the world's first scientific superintelligence platform and fully autonomous labs for life, chemical, and materials sciences. The company, which was founded in Flagship's labs in 2023, is pioneering an advanced form of AI that can not only process vast amounts of data and make predictions, but also assist scientists in designing and con
First-in-class oral selective SMARCA2 (BRM) inhibitor FHD-909 (LY4050784) continues enrollment in Phase 1 trial for SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population FHD-909 preclinical combination data with pembrolizumab and KRAS inhibitors to be presented at AACR 2025 Selective degradation of ARID1B achieved with program update expected in 2025; continued progress of Selective CBP degrader and Selective EP300 degrader towards IND Strong balance sheet with cash, cash equivalents, and marketable securities of $243.7 million as of December 31, 2024, provides cash runway into 2027 CAMBRIDGE, Mass., March 06, 2025 (GLOBE NEWSWIRE) -
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the election of Neil Gallagher, M.D., Ph.D., and Stuart Duty, to its Board of Directors. "Neil and Stuart are experienced leaders with decades of deep and multifaceted understanding of the biotechnology industry," said Adrian Gottschalk, President and Chief Executive Officer of Foghorn. "We are pleased to welcome them to our Board of Directors and will leverage their strategic insights as we further advance our pipeline." Dr. Gallagher
CAMBRIDGE, Mass., April 29, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Quotient Therapeutics, a company pioneering somatic genomics, today announced that Rahul Kakkar, M.D., will join Flagship Pioneering as CEO-Partner and Quotient Therapeutics as Chief Executive Officer. Dr. Kakkar is a biotech entrepreneur and physician-scientist with nearly 20 years of professional experience founding and building biotechnology companies and practicing medicine. Previously, he served as President and CEO of Tome Biosciences, a genome engineering biotec
Owen joins to lead new phase of growth for the medical device company in clinical trial, diagnostic, and reference laboratory applications CAMBRIDGE, Mass., Feb. 19, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and YourBio Health, a pioneer in remote blood collection technology, today announced the appointment of Paul Owen as Chief Executive Officer of YourBio Health and CEO-Partner of Flagship Pioneering. Owen joins YourBio Health and Flagship after a corporate leadership and strategic planning career spanning more than 35 years. He was most r
CAMBRIDGE, Mass., Nov. 20, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Metaphore Biotechnologies, a Flagship-founded biotechnology company designing novel therapeutics by combining machine learning and molecular mimicry, today announced that Angela Hwang, MBA, will join Flagship Pioneering as CEO-Partner, and Metaphore as Chief Executive Officer, effective January 1, 2025. Most recently, Hwang served as Chief Commercial Officer and President of the Global Biopharmaceuticals Business at Pfizer. During her tenure at Pfizer, Hwang helped brin
Williams was promoted from Operating Partner at Flagship Pioneering and President at Apriori Bio Apriori Bio has made significant progress in 2024, including securing a collaboration with CEPI, assembling a world class board of directors and building out an early pipeline of prospective vaccines CAMBRIDGE, Mass., Nov. 13, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Apriori Bio, a biotechnology company aimed at providing humanity with variant-resilient protection against rapidly-evolving viruses, today announced that Craig Williams, MBA, has been promoted to CEO-Partner at Flagship Pioneering and Chief Executive Officer of Apriori.
Valo Elevates Brett Blackman to Chief Operating Officer and Appoints Travis Wilson to its Board of Directors CAMBRIDGE, Mass., Nov. 13, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Valo Health today announced that industry leader Brian M. Alexander, M.D., M.P.H. has been appointed Chief Executive Officer of Valo Health and CEO-Partner of Flagship Pioneering. Dr. Alexander brings two decades of biotechnology, biopharma, and medical leadership, most recently as SVP, Research & Development and Head of Boston Roche Innovation Center (BRIC), for Roche/Genentech and previously as CEO of Foundation Medicine. Valo also announced the appointments of Brett Blackman
CAMBRIDGE, Masss. and LONDON, Oct. 23, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced that Junaid Bajwa, M.D., has joined its London office as Senior Partner and Head of United Kingdom. In this role, Dr. Bajwa will play an integral role in advancing new strategic opportunities and partnerships for Flagship and its ecosystem of companies in the United Kingdom and throughout Europe. Dr. Bajwa will also serve as Science Partner for Pioneering Intelligence, Flagship's strategic initiative that is building unique AI/ML knowledge to accelerate innovation across the ecosystem.
CAMBRIDGE, Mass., Oct. 9, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced that Paul Parker has joined as Managing Partner, Capital Solutions and Value Realization. In this role, Parker will lead all capital solutions efforts at Flagship, driving portfolio value realization, fundraising activities, and building and managing Flagship's relationships with Limited Partners as well as strategic and financial investors. He will also play a key role on Flagship's senior leadership team, helping drive value, impact, and effectiveness across the organization.
CAMBRIDGE, Mass., Oct. 3, 2024 /PRNewswire/ -- Invaio Sciences, a Flagship Pioneering bioplatform company focused on accelerating the leap to nature-positive agriculture, today announced the appointment of André Andonian as the new Chairman of its Board of Directors. Robert Berendes has decided to step down after serving as Chairman of the Board since 2019 and will continue to serve on the board of Invaio. Andonian is Chair of Asia Pacific and Strategic Advisor at Flagship Pioneering, where he and Ignacio Martinez are responsible partners for Invaio. He is also Senior Partner
CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Anna Rivkin, Ph.D., will join the company as Chief Business Officer (CBO), on September 3, 2024. Dr. Rivkin brings over two decades of expertise in a broad spectrum of complex business transactions across multiple disease areas. "We have significant potential in our pipeline and platform as we continue to build Foghorn," said Adrian Gottschalk, President and Chief Executive Officer of Foghorn. "During this exciting stage of growth,
Citizens JMP initiated coverage of Foghorn Therapeutics with a rating of Mkt Outperform and set a new price target of $9.00
B. Riley Securities initiated coverage of Foghorn Therapeutics with a rating of Buy and set a new price target of $10.00
Jefferies initiated coverage of Foghorn Therapeutics with a rating of Buy and set a new price target of $18.00
Evercore ISI initiated coverage of Foghorn Therapeutics with a rating of Outperform and set a new price target of $20.00
BofA Securities initiated coverage of Foghorn Therapeutics with a rating of Buy and set a new price target of $10.00
BMO Capital Markets initiated coverage of Foghorn Therapeutics with a rating of Outperform and set a new price target of $20.00
Morgan Stanley reiterated coverage of Foghorn Therapeutics with a rating of Overweight and set a new price target of $26.00 from $23.00 previously
HC Wainwright & Co. initiated coverage of Foghorn Therapeutics with a rating of Buy and set a new price target of $25.00
Morgan Stanley reiterated coverage of Foghorn Therapeutics with a rating of Overweight and set a new price target of $23.00 from $24.00 previously
DEFA14A - Foghorn Therapeutics Inc. (0001822462) (Filer)
DEF 14A - Foghorn Therapeutics Inc. (0001822462) (Filer)
8-K - Foghorn Therapeutics Inc. (0001822462) (Filer)
8-K - Foghorn Therapeutics Inc. (0001822462) (Filer)
8-K - Foghorn Therapeutics Inc. (0001822462) (Filer)
8-K - Foghorn Therapeutics Inc. (0001822462) (Filer)
424B5 - Foghorn Therapeutics Inc. (0001822462) (Filer)
8-K - Foghorn Therapeutics Inc. (0001822462) (Filer)
SCHEDULE 13G/A - Foghorn Therapeutics Inc. (0001822462) (Subject)
8-K - Foghorn Therapeutics Inc. (0001822462) (Filer)
First-in class BRM (SMARCA2) selective inhibitor FHD-909 demonstrated favorable tolerability and dose-dependent single agent activity in BRG1 mutated cancers preclinically; IND filing on track for Q2 2024 Robust preclinical monotherapy anti-tumor activity for both selective CBP and selective EP300 degrader programs Progress with FHD-909, selective CBP, and selective EP300 degrader programs further validates Foghorn's drug discovery engine Conference call and webcast today at 5 pm ET / 2 pm PT CAMBRIDGE, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseas
Company management will review key pipeline programs, including an update on FHD-286 for AML, new preclinical data for the BRM selective inhibitor FHD-909 and for its selective CBP and EP300 degrader programs Conference call and webcast on April 9th at 5 p.m. ET / 2 p.m. PT CAMBRIDGE, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- March 26, 2024 -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced plans to host a conference call and webcast on April 9th at 5 p.m. ET / 2 p.m. PT. Foghorn management will review key programs in its pipeline, inclu
4 - Foghorn Therapeutics Inc. (0001822462) (Issuer)
4 - Foghorn Therapeutics Inc. (0001822462) (Issuer)
3 - Foghorn Therapeutics Inc. (0001822462) (Issuer)
3 - Foghorn Therapeutics Inc. (0001822462) (Issuer)
4 - Foghorn Therapeutics Inc. (0001822462) (Issuer)
4 - Foghorn Therapeutics Inc. (0001822462) (Issuer)
4 - Foghorn Therapeutics Inc. (0001822462) (Issuer)
4 - Foghorn Therapeutics Inc. (0001822462) (Issuer)
4 - Foghorn Therapeutics Inc. (0001822462) (Issuer)
4 - Foghorn Therapeutics Inc. (0001822462) (Issuer)
SC 13G/A - Foghorn Therapeutics Inc. (0001822462) (Subject)
SC 13G - Foghorn Therapeutics Inc. (0001822462) (Subject)
SC 13G/A - Foghorn Therapeutics Inc. (0001822462) (Subject)
SC 13G - Foghorn Therapeutics Inc. (0001822462) (Subject)
SC 13D/A - Foghorn Therapeutics Inc. (0001822462) (Subject)
SC 13G/A - Foghorn Therapeutics Inc. (0001822462) (Subject)
SC 13G/A - Foghorn Therapeutics Inc. (0001822462) (Subject)
SC 13G/A - Foghorn Therapeutics Inc. (0001822462) (Subject)
SC 13G - Foghorn Therapeutics Inc. (0001822462) (Subject)
SC 13G - Foghorn Therapeutics Inc. (0001822462) (Subject)